CUSIP: 31189P102
Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
114,331,829
-
Total 13F shares
-
122,159,363
-
Share change
-
-920,692
-
Total reported value
-
$400,671,566
-
Put/Call ratio
-
93%
-
Price per share
-
$3.28
-
Number of holders
-
176
-
Value change
-
-$37,762,295
-
Number of buys
-
90
-
Number of sells
-
70
Quarterly Holders Quick Answers
What is CUSIP 31189P102?
CUSIP 31189P102 identifies FATE - FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q3 2024
-
Previous quarter:
Q1 2024
Recent filing periods for CUSIP 31189P102:
Institutional Holders of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) as of Q2 2024
As of 30 Jun 2024,
FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) was held by
176 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
122,159,363 shares.
The largest 10 holders included
Redmile Group, LLC, VANGUARD GROUP INC, BlackRock Inc., Boxer Capital, LLC, Deep Track Capital, LP, STATE STREET CORP, Bellevue Group AG, CITADEL ADVISORS LLC, D. E. Shaw & Co., Inc., and DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C).
This page lists
177
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.